BBIO
BridgeBio Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$67.94
+2.33%Margins
Gross margin
93.3%
EBITDA margin
-85.7%
EBIT margin
-76.2%
Net margin
-97.6%
FCF margin
-61.7%
27.7%
Return on equity
-57.2%
Return on assets
2535.0%
Return on invested capital
0.55x
Asset turnover
-$434.4M
Cash from operations
$3.68
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026